Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Tempest Therapeutics Inc is a clinical-stage biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity.
BRISBANE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated...
BRISBANE, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
Building upon a successful end-of-Phase 2 meeting, received FDA “Study May Proceed” letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced...
BRISBANE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.1072 | 14.6049046322 | 0.734 | 0.92 | 0.72 | 2163521 | 0.85493056 | CS |
4 | -0.1088 | -11.4526315789 | 0.95 | 1.0381 | 0.6986 | 1727265 | 0.83099166 | CS |
12 | -0.5488 | -39.4820143885 | 1.39 | 1.59 | 0.6986 | 3894029 | 1.03636642 | CS |
26 | -1.3088 | -60.8744186047 | 2.15 | 2.31 | 0.6986 | 3001074 | 1.22770921 | CS |
52 | -3.5088 | -80.6620689655 | 4.35 | 6 | 0.6986 | 2027661 | 1.79675522 | CS |
156 | -4.3688 | -83.8541266795 | 5.21 | 9.77 | 0.17 | 1667402 | 4.22344969 | CS |
260 | -12.9688 | -93.9087617668 | 13.81 | 41 | 0.17 | 1472916 | 4.73021122 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約